Clinical trial
Initial Combination With Pioglitazone Study (0431-064)
NCT00397631 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00397631 |
|---|---|
| Title | Initial Combination With Pioglitazone Study (0431-064) |
| Official title | A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | sitagliptin 100 mg q.d./pioglitazone 30 mg q.d, Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d. |
| Enrollment | 520 |
| Start date | Dec 19, 2006 |
| Primary completion | Jun 28, 2008 |
| Completion | Jun 28, 2008 |
| First posted | Nov 9, 2006 |
| Last update posted | May 12, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: